fda blenrep - Search News

Order byBest matchMost fresh

News

GSK, FDA and Blenrep

GSK's Blood Cancer Drug Faces US Setback Due To FDA Panel's Eye Safety Warning

FDA panel rejects GSK's Blenrep combo due to severe ocular toxicity and dosing concerns in multiple myeloma trials ahead of July 23 PDUFA decision.

Continue reading

· 5h · on MSN

GSK’s Blood Cancer Drug Blenrep Fails to Win FDA Panel Support

· 14h · on MSN

FDA Committee Votes Against GSK Blood Cancer Drug Blenrep

GSK's growth plans dented by Blenrep setback

The panel expressed concerns about the proposed doses of Blenrep (belantamab mafodotin) in GSK's marketing application, ...

Fierce Pharma2d

As GSK eyes Blenrep's US return, FDA flags eye safety concerns ahead of advisory committee meeting

GSK has been enjoying regulatory momentum in recent months as it works to bring its antibody-drug conjugate (ADC) Blenrep ...

5h

FDA votes against overall benefit/risk profile of GSK's multiple myeloma candidate at proposed dosage

Drugmaker GSK said on Friday that the US Food and Drug Administration's Oncologic Drugs Advisory Committee had voted against ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results